XenoPort to Present at the Wells Fargo Securities Healthcare Conference

  XenoPort to Present at the Wells Fargo Securities Healthcare Conference

Wells Fargo Healthcare Conference 2013

Business Wire

SANTA CLARA, Calif. -- June 11, 2013

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via
the World Wide Web to its presentation at the Wells Fargo Securities Research
& Economics 2013 Healthcare Conference. The live presentation will occur at
8:15 a.m. Pacific Time (11:15 a.m. Eastern Time) on Wednesday, June 19, 2013.
A replay of the presentation will also be available.

To access the live presentation via the Web, please go to www.XenoPort.com.
Please connect to the Web site at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may be
necessary to listen to the Webcast.

A replay of the Webcast can be accessed for a minimum of one month and will be
available approximately 24 hours after the live presentation.

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders. Horizant^® (gabapentin
enacarbil) Extended-Release Tablets is approved and being marketed in the
United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release
Tablets is approved and being marketed in Japan by Astellas Pharma Inc.
XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's
pipeline of product candidates includes potential treatments for patients with
Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.

To learn more about XenoPort, please visit the Web site at www.XenoPort.com.

Horizant, Regnite and XENOPORT are registered trademarks of XenoPort, Inc.

XNPT2G

Contact:

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com
 
Press spacebar to pause and continue. Press esc to stop.